DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant's election with traverse of group I in the reply filed on 8/24/26 is acknowledged. The traversal is on the ground(s) that searching and examining the claims 15-20 drawn to using the very same searched formula II for treating a PSMA-expressing condition or disease and imaging does not require any different searches for substituents, linker moieties and radiometal chelators. This is not found persuasive because the compounds of group I comprise so many possible variations and unlimited number of possible combinations of chemical moieties and further searching for the methods of treating and/or imaging of the infinite number of compounds of group I will cause a search burden to the Office.
The requirement is still deemed proper and is therefore made FINAL.
Claim 15-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected groups, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 8/24/26.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-9 and 11-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second
paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The instant claims are confusing and unclear as the compounds of Formula (II) comprise a Markush structure containing so many possible variations, such as the combination of R2 ,R7,R11,R12, and Rx moieties wherein R11 may be present or may not be present and the ring systems of R10 may be optionally modified to include various substituents or additional endocyclic ring nitrogen atoms. The many possible variations of the substitutions and different possible chelating moieties of different sizes and functions yields compounds of different sizes and that may form various conformations. The compounds of the instant claims comprise numerous different structures so that the scope of the claims cannot be determined. While breadth alone is not indefinite, the instant claims have an almost unlimited number of possible combinations of chemical moieties that it is not possible to determine the metes and bounds of the claims.
The dependent claims fall therewith.
Claims 11-9 and 11-14 are rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature.
A Markush claim contains an “improper Markush grouping” if: (1) the species of the Markush group do not share a single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a "single structural similarity” when they belong to the same recognized physical or chemical class or to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent (see Federal Register, Vol. 76, No. 27, Wednesday, February 9, 2011, p. 7166, left and middle columns, bridging paragraph).
The claims are directed to compounds of Formula (II) comprise a Markush structure containing so many possible variations, such as the combination of R2 ,R7,R11,R12, and Rx moieties wherein R11 may be present or may not be present and the ring systems of R10 may be optionally modified to include various substituents or additional endocyclic ring nitrogen atoms. The many possible variations substitutions and different possible chelating moieties of different sizes and functions yields compounds of different sizes and that may form various conformations. The compounds of the instant claims comprise numerous different structures so that the scope of the claim cannot be determined, instant claims have an almost unlimited number of possible combinations of chemical moieties and there is nothing of record to show a common chemical core that is specifically tied to a function in the almost unlimited breadth of the claimed compounds.
Applicant attention is directed to the third paragraph of MPEP 803.02 which discloses: “Since the decisions in In re Weber, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and In re Haas, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which Applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. In re Harnisch, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and Ex parte Hozumi, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature essential to that utility.”
In the instant case, if it is asserted that the claims share a common utility, it is noted the only
shared structures are urea and
PNG
media_image1.png
82
234
media_image1.png
Greyscale
that does not allow the genus to have an art recognized classification. Hence, the Markush grouping is improper.
In response to this rejection, Applicant should either amend the claim(s) to recite only individual
species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1) (emphasis provided).
The dependent claims fall therewith.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research
agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file
provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-9,11,13 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5,7-27,35-38,40-43 and 45-50 of copending Application No. 18/996,309 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula I
PNG
media_image2.png
112
260
media_image2.png
Greyscale
of copending Application No. 18/996,309 encompasses the
compound of Formula II
PNG
media_image3.png
110
268
media_image3.png
Greyscale
of the instant claims as they comprise the same corresponding substituents for R1a-R1c, R0, R3,
PNG
media_image4.png
24
132
media_image4.png
Greyscale
is
PNG
media_image5.png
158
152
media_image5.png
Greyscale
, R7
PNG
media_image6.png
30
102
media_image6.png
Greyscale
, especially R2 is -CH2CHF-, -CHFCH2-, -CH2OCH2-, -CH2SCH2-.
The method of imaging prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/996,309 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of imaging prostate specific membrane antigen (PSMA)-expressing tissues.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 1-9,11 and 13 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3,19-21,23,25,27,28,31-34,44,45,47,48,50-52,55 and 57-59 of copending Application No. 18/842,681 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula I
PNG
media_image7.png
208
602
media_image7.png
Greyscale
encompasses the
compound of Formula II
PNG
media_image3.png
110
268
media_image3.png
Greyscale
of the instant claims as they comprise the same corresponding substituents for R2, R3,L1-L7,R4, R5a-5b,R6,
PNG
media_image5.png
158
152
media_image5.png
Greyscale
, especially R1 is -CH2CHF-, -OCH2-, -SCH2-.
The compounds of copending Application No. 18/842,681 further comprise compounds, such as
PNG
media_image8.png
228
458
media_image8.png
Greyscale
that encompass the
PNG
media_image9.png
244
440
media_image9.png
Greyscale
of the instant claims.
The method of treating prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/842,681 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of treating prostate specific membrane
antigen (PSMA)-expressing tissues.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 1-9,11,13 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1,3,4,7-18,41-44,46 and 47 of copending Application No. 18/267,987 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula B
PNG
media_image10.png
124
378
media_image10.png
Greyscale
of copending Application No. 18/267,987 encompasses the compound of Formula II
PNG
media_image3.png
110
268
media_image3.png
Greyscale
of the instant claims as they comprise the same corresponding substituents for R1a-R1c, R0a-R0c,
PNG
media_image4.png
24
132
media_image4.png
Greyscale
is
PNG
media_image5.png
158
152
media_image5.png
Greyscale
, R7, especially R2 is -CH2CHF-, -CHFCH2-, -CH2OCH2-, -CH2SCH2-.
The compounds of copending Application No. 18/267,987 further comprise compounds, such as
PNG
media_image11.png
238
322
media_image11.png
Greyscale
that encompass the
PNG
media_image12.png
244
426
media_image12.png
Greyscale
of the instant claims.
The method of imaging and/or treating prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/267,987 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of imaging and/or treating prostate specific membrane antigen (PSMA)-expressing tissues
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Relevant Prior Art
Besenova et al.(WO 2018/215627) discloses the compounds
PNG
media_image13.png
230
434
media_image13.png
Greyscale
(p12) wherein R4 comprises F, etc. (p14) but does not disclose the F at the position corresponding to the compounds of Formula II of the instant claims.
Conclusion
No claims are allowed at this time.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA JEAN PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached M9-3, T9-3, W9-3, Th9-2, F9-2.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MELISSA J PERREIRA/Examiner, Art Unit 1618